ABCL vs PATH
Abcellera Biologics Inc (ABCL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ABCL revenue for 2024-12-31 was $28.8M. Net income was -$162.9M. Revenue was down 24.2% from 2023-12-31 to 2024-12-31. ABCL currently screens at market cap $1.12B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ABCL currently screens at market cap $1.12B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ABCL and PATH stock pages for the full models.
Not investment advice.